What is Ciloa?
Ciloa is a biotechnology firm specializing in the development of advanced therapies derived from over 15 years of research into exosome-based drug development technology. The company's proprietary technology enables the production of all types of membrane proteins in their native conformation on exosomes, as well as the loading of cytosolic proteins. This capability is particularly significant for targeting notoriously difficult-to-treat "undruggable" membrane protein targets, which are often key to groundbreaking therapies. Ciloa's exosome technology has broad applications across oncology, infectiology, cardiology, genetic diseases, and neurological disorders, leveraging the natural properties of exosomes, including their immuno-stimulatory, biocompatible, and intercellular messenger characteristics, along with their ability to cross the blood-brain barrier.
How much funding has Ciloa raised?
Ciloa has raised a total of $13M across 2 funding rounds:
Other Financing Round
$5.4M
Other Financing Round
$7.6M
Other Financing Round (2022): $5.4M with participation from Bpifrance
Other Financing Round (2025): $7.6M led by Agence nationale de la recherche ANR
Key Investors in Ciloa
Agence nationale de la recherche ANR
The Agence nationale de la recherche (ANR) is the French national agency dedicated to funding project-based research across diverse scientific fields, with a strong emphasis on sustainable development and international collaboration. It supports researchers and institutions in advancing scientific innovation.
Bpifrance
Bpifrance is a French public investment bank that provides financing, guarantees, and equity to companies at all stages of their development. It actively supports innovation, international expansion, and export activities for startups, SMEs, and mid-cap companies.
What's next for Ciloa?
With the recent major strategic investment, Ciloa is poised to accelerate its research and development initiatives, particularly in addressing challenging therapeutic targets. The company's focus on exosome technology positions it at the forefront of innovation in drug delivery and protein therapeutics. Future growth will likely involve further clinical validation of its platform and expansion into new disease areas, capitalizing on the versatility of its exosome-based approach. The strategic nature of this financing suggests a focus on scaling operations and potentially forging key partnerships to bring its therapies to market.
See full Ciloa company page
